Publication details

Vakcíny v léčbě mnohočetného myelomu.

Investor logo
Title in English Vaccines in the treatment of multiple myeloma.
Authors

BÜCHLER Tomáš MUSILOVÁ Romana KOVÁŘOVÁ Lucie HÁJEK Roman

Year of publication 2002
Type Article in Periodical
Magazine / Source Klinická onkologie
MU Faculty or unit

Faculty of Medicine

Citation
Field Oncology and hematology
Keywords multiple myeloma; vaccination; immunotherapy; dendritic cells; idiotype
Description Malignant cells in multiple myeloma produce a monoclonal immunoglobulin which is tumor-specific and can be used for the induction of T lymphocytes. Idiotypic (Id) structures are expressed at the cell surface of malignant plasma cells and allow the recognition and targeting of these cells by Id-specific T lymphocytes. The induced humoral and cellular immune response controls the growth of the malignant cell clone. Vaccination using Id-protein has been attempted in patients with multiple myeloma and other B cell malignancies. The aim of this therapy is to induce specific immune response directed against the tumor cells. Id-protein may be used for cell-free vaccines where it is administered alone or after conjugation with a suitable adjuvans, and for cellular vaccines where it is loaded into dendritic cells. We review preclinical and clinical results of Id-specific vaccinations for multiple myeloma.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info